Infusion methods for immunotherapy in head and neck cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the survival outcomes, response rates, and safety of advanced Head/Neck Squamous cancer patients receiving PD1/PDL1/CTLA4 inhibitors through intra-tumor or intra-artery infusion compared to traditional intravenous methods. The study aims to enhance local drug concentration at the tumor site, potentially improving efficacy while minimizing systemic side effects. It is a phase II-III trial designed to evaluate the benefits of these innovative delivery methods on patient survival and overall response rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Cytohistological confirmation is required for diagnosis of HNC.
2. Signed informed consent before recruiting.
3. Age between 18 to 80 years with estimated survival over 3 months.
4. ECOG score \< 2
5. Tolerable coagulation function or reversible coagulation disorders
6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR \< 2.3 or PT \< 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin \> 28 g/L；Total bilirubin \< 51 μmol/L
7. At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.
8. Patients with advanced HNC which would not be suitable for treatment with loco-regional therapies or have progressed following locoregional therapy such as surgical resection and other treatment.
9. Birth control.
10. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.

Exclusion Criteria:

1. Patients participated in other clinical trials of equipment or drugs (signed informed consent) within 4 weeks;
2. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;
3. Patients accompanied with other tumors or past medical history of malignancy;
4. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment;
5. Patients have poor compliance.

   Any contraindications for neck artery infusion procedure:

   A. Impaired clotting test (platelet count \< 60000/mm3, prothrombin activity \< 50%).

   B. Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C. Known severe atheromatosis. D. Known uncontrolled blood hypertension (\> 160/100 mm/Hg).
6. Allergic to adriamycin chemotherapy drugs，contrast agent or lipiodol;
7. Any agents which could affect the absorption or pharmacokinetics of the study drugs
8. Subjects unable to suffer the discomfort of the artery infusion procedure

Where it's running

• The Second Affiliated Hospital of Guangzhou Medical University
  Guanzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Hui Lian, MD — Second Affiliated Hospital of Guangzhou Medical University
• Study coordinator: Hui Lian, MD
• Email: lian-hui-2008@163.com
• Phone: 02034153532

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RC001 in Children with Dravet Syndrome: A Safe, Investigational Test in 2-18 Year Olds

  This study tests RC001 given into the spine to see if it is safe and tolerable in kids with Dravet syndrome aged 2 to 18 who have SCN1A mutations.

  Recruiting Early Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT07675746

• Comparing three-drug blood sugar regimens for adults newly diagnosed with type 2 diabetes

  This test compares semaglutide versus sitagliptin, each given with metformin and empagliflozin, to see which better controls blood sugar and promotes remission in adults newly diagnosed with type 2 diabetes and HbA1c ≥ 9%.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT07374328

• Combining Lenvatinib with SIRT for Advanced Liver Cancer

  This study is testing whether combining a cancer drug called lenvatinib with a type of radiation therapy can help people with advanced liver cancer that hasn't improved with other treatments.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904196

• Combination treatment for large liver cancer with portal vein involvement

  This study is testing a new combination treatment for people with large liver cancer that has spread to the portal vein to see if it works better than the standard treatment.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904183

• Yttrium-90 treatment for large liver cancer

  This study is testing whether a special radiation treatment using yttrium-90 can help people with large liver cancer that can’t be surgically removed feel better and live longer.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong and 1 other locations · NCT06707233

• Neoadjuvant double immunotherapy for lung cancer treatment

  This study is testing a new way to treat early-stage lung cancer by using a combination of two immune therapies injected directly into the tumor to see if it helps patients feel better and live longer.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guanzhou, Guangdong · NCT06492421

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.